Compare Citius Pharmaceuticals Inc (CTXR) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Howmet Aerospace Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Howmet Aerospace Inc trades at $225.24 (market cap $88.76B). The key difference: Howmet Aerospace Inc is far larger — about 6516.9× Citius Pharmaceuticals Inc's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Howmet Aerospace Inc for 35 Days on average.
| CTXR | HWM | |
|---|---|---|
Market Cap | $13.62M | $88.76B |
Volume | 132,438 | 2,648,516 |
Sector | Health | Industrials |
52-Week High | $1.82 | $292.65 |
52-Week Low | $0.48 | $184.09 |
Typical Hold Time | 17 Days | 35 Days |
Enterprise Value | $3.79M | $92.86B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Howmet Aerospace (HWM) trades at $222.53, down 0.08% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with revenue and earnings growth, a net income margin of 20.52%, and consistent quarterly EPS beats. Analyst consensus is overwhelmingly bullish with a $328.10 price target, supported by positive news on defense and aerospace demand.
The outlook for HWM is positive due to robust financial performance and sector tailwinds, but risks include technical weakness and competitive pressures. Investment opportunity lies in its growth trajectory and shareholder returns, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
